Cyfuse Biomedical K.K. (TYO:4892)
Japan
· Delayed Price · Currency is JPY 621.00
-19.00 (-2.97%)
Mar 9, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Company Description
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine-related products in Japan and the United States.
The company develops cellular products for the regenerative medicine and cellular therapy fields; and undertakes various contracts for research cell products.
It also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells.
Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.
Cyfuse Biomedical K.K.
| Country | Japan |
| Founded | 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Shizuka Akieda |
Contact Details
Address: South Tower, Sumitomo Fudosan Tokyo Mita Minato, 108-6301 Japan | |
| Phone | 81 3 6435 1885 |
| Website | cyfusebio.com |
Stock Details
| Ticker Symbol | 4892 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3311800001 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Shizuka Akieda | Chief Executive Officer |
| Masahiro Sanjo | Chief Financial Officer |